Seaside Therapeutics Appoints Tanya Lewis to the Key Position of Vice President, Regulatory Affairs and Quality Assurance

Seaside Therapeutics Appoints Tanya Lewis to the Key Position of Vice President, Regulatory Affairs and Quality Assurance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seaside Therapeutics LLC announced today the appointment of Tanya N. Lewis to the position of Vice President, Regulatory Affairs and Quality Assurance.

"Seaside continues to make significant progress in the clinic with two Phase 2 studies of STX-209 well underway in Fragile X Syndrome and autism, as well as the recent initiation of the STX107 clinical program which is expected to begin enrolling individuals with Fragile X in the second half of 2010," said Randall L. Carpenter, M.D., President and Chief Executive Officer of Seaside Therapeutics. "Tanya's deep experience in developing and implementing regulatory strategy will play an important role in the continued advancement of our ongoing clinical programs and the initiation of new programs later next year. She is a valuable addition to the team and we look forward to working with her in this newly created role as we develop therapeutics to correct or improve disorders of brain development."

Ms. Lewis joins Seaside Therapeutics with over twelve years of regulatory and quality affairs experience. Prior to Seaside, Ms. Lewis played a critical role in determining regulatory strategy and interacting with the U.S. Food and Drug Administration in leadership positions at several high-growth life science companies. Most recently she was Vice President, Regulatory Affairs and Quality Assurance for Vion Pharmaceuticals, Inc. and prior positions include leadership roles at Millennium Pharmaceuticals Inc. (later acquired by Takeda Pharmaceutical Company Limited ) and Genzyme Corporation. Ms. Lewis has a Masters of Science from the Massachusetts College of Pharmacy and Allied Health Sciences with a concentration in regulatory affairs and health policy.

About Seaside Therapeutics

Seaside Therapeutics is creating novel drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development. We are dedicated to translating breakthrough discoveries in neurobiology into therapeutics that improve the lives of patients and their families. For more information visit

Seaside Therapeutics LLC
Daniel E. Geffken, 617-374-9009, ext. 1012
Chief Operating Officer
MacDougall Biomedical Communications
Sarah Cavanaugh or Kari Watson, 781-235-3060


Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.